Breast Cancer
Conditions
Keywords
multidisciplinary team, exercise, nutrition, cardiology, physiotherapy, imaging
Brief summary
People with breast cancer often experience many short and long-term side effects as a result of both the cancer and the necessary treatments. Receiving extra assessments and care from teams of multiple health professionals has been shown to be helpful for people with other health problems, such as heart disease. These 'multidisciplinary' teams may include nurses, doctors, pharmacists, dietitians, exercise therapists, counselors, and other specialists. Currently, the investigators do not know if receiving extra assessments from a multidisciplinary team is helpful for people receiving cancer treatment. In this study, the investigators hope to learn the effect of extra assessments and early interventions from teams of health care professionals in people diagnosed with cancer, during and after the treatment period. After initial assessments, participants will be randomized to multidisciplinary team intervention or usual care.
Interventions
BEHAVIORALMultidisciplinary team intervention
Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
Sponsors
University of Alberta
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Supportive care intervention
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* histologically confirmed malignancy (breast or lymphoma); * scheduled to receive anthracycline and/or trastuzumab-based chemotherapy; * age ≥ 18 years; * willing to attend follow-up visits.
Exclusion criteria
* physical disability preventing exercise testing or DEXA scan; * psychiatric disease or disorder precluding informed consent; * participation in other cardiotoxicity or exercise intervention study; * contraindication to anti-cancer therapy, including known heart failure, cardiomyopathy, or baseline LVEF \< 50%; * previous anthracycline or trastuzumab-based therapy; * previous radiotherapy to thorax.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cardiac MRI | change from baseline to 12 months | left ventricular ejection fraction (LVEF) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum biomarkers | change from baseline to 12 months | percent change in established biomarkers (troponin, BNP) |
Countries
Canada
Outcome results
None listed